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RESUMO – A dermatite de contacto inclui qualquer reação inflamatória da pele, secundária a contato direto ou indireto entre 
esta e agentes agressores. A expressão clínica mais comum é o eczema, ou outros padrões resultantes de reações retardadas, 
mas reações imediatas como a urticária de contacto podem também ocorrer. O espectro de manifestações clínicas por urticária 
de contacto é amplo. Na sua forma mais limitada, manifesta-se por urticária localizada à área de contacto entre o alergénio e a 
pele ou mucosa, e nos casos de apresentações mais exuberantes, podem surgir lesões urticariformes generalizadas, angioedema, 
ou mesmo anafilaxia. Em teoria, todos os fármacos tópicos podem ser responsáveis por urticária de contacto, e vários fármacos 
foram já descritos como indutores. As moléculas implicadas podem ser os princípios ativos ou os excipientes, por via de mecanis-
mos imunológicos ou não. Os autores apresentam uma revisão dos diferentes fármacos descritos na urticária de contacto, dando 
enfâse à urticária de contacto das mucosas e em contexto profissional.
PALAVRAS-CHAVE – Anafilaxia/induzida quimicamente; Dermatite Alérgica de Contacto; Dermatite de Contacto; Hipersensibili-
dade a Medicamentos; Urticária/induzida quimicamente. 
CONTACT URTICARIA INDUCED BY DRUGS 
ABSTRACT – Contact dermatitis includes any inflammatory skin reaction due to direct or indirect skin contact with noxious agents. 
The main clinical expression is eczema and other delayed reactions, but immediate reactions, namely contact urticaria, can also 
occur. Contact urticaria has a broad range of clinical manifestations. The limited form is restricted to the area of contact between 
the allergen and the skin or mucosa, but more severe presentations include generalized urticaria lesions, angioedema and even ana-
phylaxis. All topical drugs can theoretically precipitate contact urticaria. The culprit may be either the active compound or the exci-
pients, and the mechanisms of the immediate reactions can be both immune-mediated (IgE-dependent) and non-immune-mediated. 
The authors present an overview of the different drugs reported to induce contact urticaria, emphasizing the specific contexts of mu-
cosal exposure and contact urticaria induced by drugs in occupational settings. 
KEY-WORDS – Anaphylaxis/chemically induced; Dermatitis, Contact; Dermatitis, Allergic Contact; Drug Hypersensitivity; Urticaria/
chemically induced. 
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1. INTRODUCTION
Contact dermatitis includes any inflammatory skin reac-
tion due to direct or indirect skin contact with noxious agents. 
The main clinical expression is eczema, but other delayed 
reactions can occur (lichenoid, sarcoidal, and lymphomatous 
reactions, purpura and erythema multiform-like reactions); as 
well as immediate reactions, namely contact urticaria (CU) or 
protein-contact dermatitis.1,2
CU is not rare, particularly among atopic individuals; 
however, prevalence data are limited because the disease 
often remains undiagnosed due to the mildness of symptoms.3 
Contact urticaria syndrome (CUS) is classified according to cli-
nical severity: stage 1) urticaria localized to the area of contact 
with the offending drug; stage 2) generalized urticaria; stage 
3) urticaria with associated systemic symptoms; and stage 4) 
anaphylaxis.4,5
A CU reaction occurs within minutes to 1 hour after cuta-
neous or mucosal exposure to a substance, and clears com-
pletely within hours, and no residual signs. Proteins (molecular 
weight 10,000 to several hundred thousand) and chemicals 
(molecular weights below 1,000) can both trigger CUS.1 Vir-
tually any topical drug can induce an immediate reaction, but 
most cases have been described with topical antibiotics, NSAI-
Ds and anesthetics, and more recently, with antiseptics such 
as chlorhexidine (Table 1). Published reports of CU induced by 
other drugs represent relatively exceptional cases.
Drugs intended for systemic use (oral or i.v.) can also cause 
immediate cutaneous contact symptoms upon direct contact 
or airborne exposure.6-9 Immediate symptoms have been des-
cribed with oral drugs, generally initiated during their transient 
passage in the mouth before swallowing, inducing local symp-
toms with edema of the lips, oral and oropharyngeal muco-
sae; and such cases can progress to systemic urticaria.
When exposure occurs through mucosa or through skin 
wounds, CU onset is usually more rapid than via normal skin, 
probably due to an easier access of the offending drug to der-
mal mast cells. Moreover, mucosa exposure is more frequen-
tly associated with systemic symptoms, including anaphylaxis, 
which can be life-threatening.10,11
2. PATHOGENESIS
Drugs intended for skin application are usually small reac-
tive compounds that can easily penetrate the epidermis, and 
eventually reach the dermis, where they can activate the me-
chanisms responsible for immediate symptoms. Drugs can 
induce both immune-mediated and non-immune-mediated 
CUS, the latter being more frequent.12
In case of non-immunologic mechanisms, drugs directly 
interfere with cutaneous mast cells and induce non-specific 
degranulation, or may interfere with other neurologic and 
vascular mediators (prostaglandins/leukotrienes, PAF, subs-
tance P or other neuropeptides), resulting in increased vas-
cular permeability, vasodilation, dermal edema and pruritus. 
The mechanisms of non-immune-mediated, drug-induced im-
mediate contact reactions have not been precisely studied for 
most drugs, but causal mechanisms have been identified in 
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Table 1 - Main drugs causing contact urticaria syndrome.
ANTIBIOTICS NSAIDS ANTISEPTICS, PRESERVATIVES MISCELLANEOUS
Penicillin, mezlocillin Acetylsalicylic acid Chlorhexidine Capsaicin Corticosteroids
Ampicillin, amoxicillin Diclofenac Povidone iodine Nicotinic acid esters Cisplatin
Cephalosporins Ketoprofen Formaldehyde Chloroform Mechlorethamine
Rifampicin, rifamycin Etofenamate 2-phenpoxyethanol Dimethylsulfoxide Phenothiazides
Chloramphenicol Pyrazolones Benzoic acid Tar extracts Chlorpromazine
Gentamicin, neomycin Metamizole Sorbic acid Tincture of benzoin Levopromazine
Streptomycin Aminophenazone Chlorocresol Dinitrochlorobenzene Benzoyl peroxide
Bacitracin Prophylphenazone/ascein Perfumes Diphenylcyclopropenone Donezepil
Levofloxacin Anti-histamines Cinnamic aldehyde Pentamidine isethionate Guanidinium salts
Sodium fusidate Promethazine Balsam of Peru Pilocarpine Lindane
Virginiamycin Local anesthetics Cyclopentolate hydrochloride Uranium salts
Iodochlorhydroxyquin Benzocaine/  tetracaine Carboxymethylcellulose sodium Guar gum
Polymyxin B Lidocaine Ethylene oxide
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particular cases, including the example of capsaicin, which 
releases substance P from nerve endings4 (Table 2).
Drugs can also be specifically recognized by IgE on mast 
cells, basophils, and eventually by Langerhans cells, and other 
skin dendritic cells. In these cases, drugs likely act as haptens 
and combine with proteins (human serum albumin or other 
serum or skin proteins) prior to IgE recognition (Table 2).13 IgE 
recognition on mast cells and basophils can trigger a sequen-
ce of signaling events that result in cell degranulation, and 
release of histamine, cytokines, and other pre-formed media-
tors, or else activate phospholipase A, to release arachidonic 
acid for pro-inflammatory pathway.4
IgE-dependent CU that is induced by drugs or other agents, 
is usually more severe than CU induced by non-immunologic 
reactions, often extending beyond the application area, and 
being associated with facial angioedema, oropharyngeal 
edema or conjunctivitis; and with systemic symptoms such as 
cough, bronchospasm, dyspnea, abdominal cramps and, in 
some cases, anaphylaxis with bradycardia and hypotension.4
It is important to underline that both immediate and de-
layed hypersensitivity mechanisms may be concomitantly in-
volved for a single agent, as in chlorocresol, an excipient of 
corticosteroid creams, or as in occupational airborne disin-
fectants.6
3. CU FROM TOPICAL DRUGS APPLIED ON THE SKIN
Many topical drugs used either on normal or damaged skin 
cause CUS. Both the active ingredient and a component of the 
vehicle can be responsible, and most represent a non-immu-
nological reaction induced by perfumes or preservatives.5,14,15 
Some of these immediate reactions manifest only as tran-
sient erythema and tingling, or as pruritus without wheals, 
usually resolving in less than 30-60 minutes. Therefore, they 
are not usually the subject of publication or more detailed 
study.
3.1. Topical antibiotics
CU in response to topical antibiotics is not frequent, but 
although only a few cases have been described they can be 
severe. Most published cases of CU or more severe immedia-
te reactions from topical antibiotics are rather old, similarly to 
those induced by bacitracin and polymyxin B,16 rifamycin,8,17 
chloramphenicol, gentamycin, streptomycin, neomycin18 and 
viginiamycin.4 Nevertheless, a recent case reported CUS with 
severe systemic symptoms in a 16 year-old boy, following the 
use of sodium fusidate applied to skin with abrasions.9
Topical antibiotics are often used on skin with barrier de-
fects, or even on open wounds or ulcers. This may favor sen-
sitization and/or the effector reaction, due to easier access 
of the drug to the dermis. Also, in infected or wounded skin, 
previous activation of the innate immune system by pathogens 
and their pathogen-associated molecular patterns (PAMP), by 
inflammatory molecules and by danger-associated molecular 
patterns (DAMPs), may additionally facilitate a specific immu-
ne response that exacerbates the urticarial reaction.
3.2. Topical antihistamines and NSAIDs
Immediate reactions have been described with topical an-
tihistamines such as promethazine; and with topical NSAIDs 
such as acetylsalicylic, metamizol and other pyrazolone com-
pounds,4,19,20 diclofenac,21 etofenamate22 and ketoprofen23; 
and other drugs such as aescin.24 However, those reports were 
mostly isolated cases, dating back to the 1990s.
3.3. Topical anesthetics
Local anesthetics applied on normal skin have been des-
cribed as a cause of CU, namely benzocaine cream18 and es-
pecially creams containing lidocaine. Contrasting with its low 
capacity to induce delayed hypersensitivity reactions,25 lido-
caine has caused CU in a hemorrhoidal cream7; in a combi-
nation of lidocaine and tetracaine (7% each)26; and in EMLA® 
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Table 2 - Contact urticaria mechanisms.
Non-IgE dependent mechanism Proposed and demonstrated* mechanisms
Drug-specific IgE dependent mechanism 
(Drug-specific IgE identified)
Etofenamate, diclofenac, ketoprofen, 
acetylsalicylic acid and other topical NSAIDs
Imbalance between prostaglandins and 
leukotrienes
Betalactam antibiotics
Benzoic acid and sorbic acid Prostaglandin D2 release* Bacitracin
Capsaicin Release of substance P from nerve endings Chlorhexidine
Rifamycin - Topical anesthetics
Cannabis - NSAID
Local anesthetics - Formaldehyde
Perfumes -
474
GPDEC
cream, an eutectic mixture of lidocaine and prilocaine at 2.5% 
each.25
3.4. Topical antiseptics
Topical antiseptics such as povidone iodine27,28 and 
chlorhexidine29,30 are particularly involved in immediate reac-
tions when applied to surgical or other open wounds, or to 
the mucosa.
4. CONTACT URTICARIA FROM MUCOSAL EXPOSU-
RE TO DRUGS
Exposure through mucosa is often associated with more 
rapid onset of reaction and more severe symptoms, even upon 
very discrete exposure to the offending drug.
The conjunctiva has been the exposure site for localized 
or generalized urticaria or even anaphylaxis induced by eye 
drops, i.e. levofloxacin and mydriatic cyclopentolate hydro-
chloride eye drops.31-33
The oral mucosa has been the exposure site for cases of 
CU induced by anesthetic gels containing lidocaine and guar 
gum in the excipient34; by chlorhexidine used in dental endo-
dontic procedures,30 mouth washes10 and toohtpastes35; and 
also by formaldehyde used in dental procedures.36
Exposure of the vaginal mucosa to chlorhexidine29 or po-
vidone iodine37 during gynecological procedures has been 
associated with generalized urticaria. Chlorhexidine has also 
been involved in CU after the insertion of central catheters or 
intra-urethral catheters soaked in this antiseptic, namely Ins-
tillagel®, which contains both chlorhexidine and lidocaine.38
Perioperative urticaria or anaphylaxis can also be a pre-
sentation of CU, mainly by contact with latex or ethylene oxide 
used for the disinfection of material (masks),38 but also by the 
antiseptics chlorhexidine and povidone iodine,21 or by the an-
tibiotics rifamycin and bacitracin used for surgical wound di-
sinfection.29
5. CONTACT URTICARIA FROM DRUGS IN OCCUPA-
TIONAL SETTINGS
Occupational CU from drugs occurs mainly in nurses who 
prepare injectable drugs, and in nurses and other caregivers 
who are required to crush and handle tablets.39 CU in the 
pharmaceutical industry is rare, as most drugs are produced 
in closed circuits involving little or no contact with the worker.5 
The main allergen associated with CU among the health care 
population is latex, although the incidence has declined sig-
nificantly in recent years by improving latex production and 
through the use of powder-free gloves.3
Frequent chronic hand eczema in nurses, due to irrita-
tion, delayed allergy, or atopic dermatitis, consequently with 
a disturbed skin barrier, may contribute to enhanced drug 
penetration through the epidermis and thereby easier access 
of potential allergens to dermal mast cells. Continuous hand 
exposure to drugs recognized by IgE can also induce imme-
diate vesicular reactions; as in protein contact dermatitis, this 
can contribute significantly to aggravation and persistence of 
chronic hand eczema in this occupational setting.40
Nurses with occupational CU mostly complain of transient 
hand edema or swelling in association with pruritus or pa-
resthesia. Lesions on the face, neck and forearms can also 
occur, eventually with generalization of urticaria and systemic 
symptoms (cough, dyspnea, asthma, rhinorrhea or abdominal 
cramps), particularly upon airborne exposure to volatile subs-
tances or powders of the drug.41
The drugs primarily associated with occupational CU are 
the antibiotics, particularly penicillin, ampicillin, amoxicillin and 
the cephalosporins.38,42,43 Apart from antibiotics, other drug-in-
duced cases of CU have been reported in health care workers, 
namely with chlorhexidine, donepezil, and cisplatin.34,44,45
6. DIAGNOSIS OF IMMEDIATE SYMPTOMS INDU-
CED BY DRUGS
The diagnosis of CU induced by drugs is based mainly on 
clinical history, which requires very precise data on the timing 
of events (drug exposure and initiation of symptoms), and the 
localization of lesions (initial localization and progression).
When urticaria is preceded by exposure to multiple drugs 
(topical and systemic), it is extremely important to perform 
complementary tests in order to achieve a precise diagnosis, 
and to enable the culprit drug to be avoided in future. When 
the patient has been exposed to a single drug, complementary 
tests may be important to confirm the etiology, evaluate cross-
-reactivity to related chemicals,46 to identify a safe alternative 
drug and, eventually, to appreciate the participation of drug-
-specific IgE.
The development of urticaria or anaphylaxis preoperative-
ly is often incorrectly attributed to systemic drugs, as they are 
the main cause of urticaria in these settings (neuromuscular 
blockers, antibiotics, anesthetics, opiates, analgesics such as 
metamizol or radiocontrast media).11,29 However, topical drugs 
can be the cause, as shown in a recent study where chlorhexi-
dine represented 5% of all perioperative anaphylaxis cases.29
To prevent avoidable cases of severe reactions during skin 
testing, the study of such patients should begin with open epi-
cutaneous tests in normal skin, and occlusive patch tests on the 
forearms with immediate readings (20-30 minutes). If negati-
ve, they should be followed by skin prick tests, and eventually, 
by intracutaneous tests (Fig. 1). These tests should be perfor-
med in settings where there is easy access to resuscitation 
measures, since generalization of urticaria from skin testing, 
or even anaphylaxis36,38 can occur, particularly in the study of 
severe CU or anaphylactic reactions. When organs other than 
skin are involved, it is important to begin testing with a diluted 
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allergen. Nevertheless, there are few standardized drug pre-
parations for skin testing, namely for epicutaneous patch tes-
ting, and even fewer for skin prick or intracutaneous testing.
Topical drugs and dressings can be tested as such in open 
epicutaneous tests, on the volar forearm; subsequently, a lan-
cet puncture can be performed across the material applied 
to the skin. For prick testing with drugs, sterile dilutions from 
commercial preparations have to be performed, preferably 
from i.v. preparations. There is no consensus on the dilutions 
to be used, but in more severe reactions it is advisable to 
begin with higher dilutions and to increase the concentration 
progressively in case of negative tests (10-3, 10-2, 10-1, then 
pure), or to follow the concentrations recommended by the 
ESCD46 and ENDA/EAACI study groups47 for the assessment 
of adverse effects of systemic drugs.
Results have always to be compared with the positive 
control (histamine 10mg/ml) and negative control (saline). 
According to the guidelines for prick testing, only papular 
erythematous reactions with a diameter >3mm are conside-
red positive.46
The sensitivity of in vivo testing is usually higher than in vitro 
tests, but it is important to be aware that some drugs (opioids, 
non-steroidal anti-inflammatory drugs - NSAIDs) cause non-
-specific mast cell degranulation and, consequently, false-po-
sitive reactions. Therefore, in positive results, particularly with 
unknown drugs, skin testing in at least 20 control patients is 
mandatory to confirm the specificity of the positive reaction.
Reagents for specific IgE (in vitro test) are commercialized 
only for a limited number of drugs and excipients potentially 
involved in CU, namely beta-lactam antibiotics, chlorhexidi-
ne, formaldehyde, ethylene oxide and gelatin, and for a few 
others that can cause urticaria upon systemic exposure.48,49 
BAT (basophil activation tests) evaluation for degranulation 
of basophils upon in vitro exposure to the chemical, and the 
increase in basophil expression of CD63 or CD203c evaluated 
by flow cytometer, can be performed in selected laboratories, 
but these tests are less specific.50 Measuring serum tryptase 
during the acute episode, or within the first 2-4 hours after a 
stage 3 CUS or anaphylaxis, and comparison with basal va-
lues (>24h), is a useful complementary test to document mast 
cell/basophil degranulation, but does not confirm the etiology 
of the reaction.37 Controlled exposure to the suspected drug, 
or to safe alternative drugs may be advisable when all pre-
vious tests were negative.
7. CONCLUSIONS
Topical drugs, or occasionally systemic drugs, that come 
into contact with the skin or mucosa may induce CU, which is 
often overlooked because some reactions are mild and igno-
red by patients. Moreover, as such effects are transient, they 
are seldom present at the time of consultation or at the time of 
testing, which makes diagnosis difficult. Complementary tests 
(skin tests with immediate readings and, eventually, in vitro 
tests) are mandatory in certain situations, as precise diagnosis 
of the culprit drug and identification of safe alternative drugs 
can be life-saving.
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